In This Article:
-
Net Loss (Q4 2024): $31.4 million or $0.54 per share.
-
Net Loss (Full Year 2024): $156.8 million or $2.70 per share.
-
Cash and Investments (as of Dec 31, 2024): Over $90 million.
-
Costs and Expenses (Q4 2024): $35.7 million, a slight increase from the previous quarter.
-
Interest Expense (Q4 2024): $3.2 million, $1 million lower than Q3 2024.
-
OMIDRIA Royalties (Q4 2024): $10.1 million based on net sales of $33.6 million.
-
OMIDRIA Net Sales (Q4 2024): $33.6 million, an increase from $31 million in Q3 2024.
-
Income from Discontinued Operations (Q4 2024): $5.2 million.
Release Date: March 31, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Omeros Corp (NASDAQ:OMER) has resubmitted its Biologics License Application (BLA) for narsoplimab in the treatment of TA-TMA, with a PDUFA date set for September, indicating progress towards potential approval.
-
The company has over $90 million in cash and investments, providing a financial cushion to support ongoing operations and development programs.
-
Omeros Corp (NASDAQ:OMER) is actively pursuing partnerships and other financial strategies, such as royalty monetization and equity transactions, to strengthen its financial position.
-
The company has a robust pipeline, including the development of zaltenibart for PNH, which is in Phase 3 trials, and OMS1029, a next-generation MASP-2 inhibitor.
-
Omeros Corp (NASDAQ:OMER) has established strong relationships with key transplant centers in the US, positioning it well for the potential launch of narsoplimab.
Negative Points
-
Omeros Corp (NASDAQ:OMER) reported a significant net loss of $156.8 million for the full year 2024, highlighting ongoing financial challenges.
-
The company is in preliminary discussions to restructure its 2026 convertible notes, indicating potential financial strain and the need for debt management.
-
There is uncertainty regarding the pricing strategy for narsoplimab, which could impact market acceptance and revenue generation.
-
The company faces competition in the complement inhibitor space, which could affect the market share and success of its products.
-
Omeros Corp (NASDAQ:OMER) has not yet disclosed specific plans for ex-US commercialization of its products, which could limit its global market reach.
Q & A Highlights
Q: Can you explain why you believe the resubmission of the BLA for narsoplimab is strong and what the implications are? A: Gregory Demopulos, CEO, explained that the statistical analysis plan was created with FDA's agreement, and the results are impressively strong across all analyses. The primary analysis showed a more than threefold improvement in survival with a P value of less than 0.00001, indicating statistically significant and clinically meaningful results. Catherine Melfi, Chief Regulatory Officer, added that the package is solid due to a well-matched external control group and strong results.